Diabetes mellitus is an endocrine disorder that is associated with several microvascular and macrovascular complications in addition to complications within the central nervous system (CNS). Diabetic encephalopathy secondary to chronic hyperglycemia is mediated through oxidative stress, increased advanced glycation end products (AGEs), and impairment in cerebral insulin signaling. The Aim of the work was to investigate whether inhibition of aldose reductase and arginase enzyme can protect against vascular and behavior complications.
INTRODUCTION
Diabetes mellitus is an endocrine disorder resulting from inadequate insulin release and/or reduced insulin sensitivity.
Diabetes-induced microvascular changes can alter the diameter of resistance arteries thereby affecting cardiac output and the distribution of blood flow (Song et al., 2008) . The complications of diabetes are well characterized in peripheral tissues and there is a growing appreciation that the complications of diabetes extend to the central nervous system (CNS) (Reagan, 2012) .
In diabetes, the gradual development of complications in the CNS is termed "diabetic encephalopathy" which is characterized by brain neurophysiological and structural changes, leading to impairment of cognitive function (Taurino et al., 2012) .
Diabetes-related cognitive dysfunction is a consequence of changes within CNS that are secondary to chronic hyperglycemia (Malone et al., 2006) . The cerebrovascular changes, oxidative stress, increased advanced glycation end products (AGEs), and impairment in cerebral insulin signaling are thought to be the underlying causes for diabetic dementia (Bhutada et al., 2010) .
The polyol pathway which is responsible for reducing glucose to sorbitol via aldose reductase enzyme (AR) (He et al., 2011 ) is activated in diabetic conditions resulting in accumulation of sorbitol (SOR) (Nakano et al., 2003) . Osmotic stress due to accumulation of sorbitol and oxidative stress due to changes in the Zagazig J. Pharm. Sci. June, 2014 ISSN 1110-5089 Vol. 23, Issue. 1, pp, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] ratio of NADPH/NADP are major causes of various complications of diabetes (Srivastava et al., 2005) .
Ferulic acid is a natural polyphenol which is known to inhibit AR and has antioxidant, hypotensive, and anti-inflammatory properties (Badawy et al., 2013) . Cinnamaldehyde is another AR inhibitor (Lee, 2002) which has antioxidant, anti-inflammatory, immunomodulatory (Chao et al., 2008) , and antidiabetic actions (Zhang et al., 2008) .
Activation of arginase enzyme in diabetes (Jiang et al., 2003) leads to competition with endothelial nitric oxide synthase (NOS) for the common substrate arginine (Romero et al., 2008) , which results in the decrease in NO (Kubes et al., 1991) and increase in superoxide production (Caldwell et al., 2010) , ultimately causing several diabetic complications such as vascular and endothelial dysfunction (Romero et al., 2008) .
L-norvaline, L-citrulline and Lornithine are amino acids that work as arginase inhibitors (El-Bassossy et al., 2012b).
The present study was designed to investigate the impact of diabetes on animal behavior and also the possible role of aldose reductase and arginase inhibitors in ameliorating these diabetic complications.
MATERIALS and METHODS Animals
Adult male wistar rats weighing 170±20 g were obtained from the National Research Institute (Cairo, Egypt) and housed in clear polypropylene cages (5 rats per cage) and kept on a 12/12 light -dark cycles under constant environmental conditions. Rats were fed normal pellet diet and water ad libitum. Experimental design and animal handling procedures were approved by the Ethical Committee for Animal Handling at Zagazig University (ECAHZU).
Study protocol
Diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ, 50 mg/kg) in cold normal saline (Ramanathan et al., 1998) . Diabetes was confirmed by stable hyperglycemia (≥ 300mg/dl) after 3 days of STZ injection. Rats were given 8 weeks after STZ injection to develop vascular complications (Badawy et al., 2013) . Then rats were randomly distributed among eight experimental groups (n = 6) and were orally treated with ferulic acid (20 mg/kg ) (Badawy et al., 2013), gliclazide (10 mg/kg), cinnmaldehyde (20 mg/kg ) (El-Bassossy et al., 2011) daily as a suspension in 0.5% carboxy methyl cellulose (CMC), citrulline (50 mg/kg), norvaline (50 mg/kg) or ornithine (200 mg/kg) daily in distilled water (El-Bassossy et al., 2012a) for 8 weeks.
Twelve hrs after the last injection, body weight, blood glucose were measured (Glucometer Bionime GM100 Blood Glucose Meter) and blood pressure was recorded (Power Lab 26T, LTS) in a conscious and slightly restrained rat by tail cuff method as previously described (ElBassossy et al., 2012a). Behavior changes were assessed in Y-maze and elevated plus maze. Performance in Ymaze was recorded as score; 0: no entrance to target arm,1: enter target arm only & stay in it, 2: enter nontarget arm first then target arm, 3: enter target arm first and pass three arms in more than four minutes, 4: enter target arm first and pass three arms within four minutes, 5: enter target arm first and pass three arms in less than one minute (Baluchnejadmojarad and Roghani, 2011; Nasri et al., 2012 
Statistical analysis
Data are expressed as mean ± SEM.
Statistical analysis was performed using one way analysis of variance (ANOVA) followed by Tukey's post Hoc test at P ˂ 0.05 using Graphpad Prism software ® .
RESULTS

Body weight
Diabetes was associated with a significant decrease in body weight after 4 month in comparison to control rats (204 vs 288.3 gm). Oral administration of ferulic acid, cinnamaldehyde, norvalline, cirtulline, ornithine and gliclazide did not cause any significant change in body weight (fig 1a) . Figure 1b shows a significant increase in blood glucose in diabetic rats after two and four months of STZ injection in comparison to control rats (440 and 514.7 vs 112.2 mg/dl respectively). Meanwhile, treatment with ferulic acid, cinnamaldehyde, norvalline, cirtulline, ornithine and gliclazide failed to cause any significant change in blood glucose. Data are expressed as mean ± SEM, n = 6. * significantly different from control group at P<0.05 using one way analysis of variance (ANOVA) followed by Tukeys Post Hoc test. Figure 2 shows that 4 month of diabetes caused a significant increase in systolic and diastolic blood pressure in comparison to control rats (135.3 vs 114 mmHg and 106.6 vs 73.83 mmHg respectively). Oral administration of gliclazide lead to a significant reduction in systolic and diastolic blood pressure in comparison to diabetic rats (117.7 vs 135.3 mmHg and 77.5 vs 106.6 mmHg respectively) as shown in Figure 2a Data are expressed as mean ± SEM, n = 6. * significantly different from control group, # significantly different from diabetic group at P<0.05 using one way analysis of variance (ANOVA) followed by Tukeys Post Hoc test. Figure 3 shows that 4 months of diabetes induced a significant decrease in Y-maze score in comparison to control rats (1.5 vs 4.7), while treatment with ferulic acid, cinnamaldehyde, citrulline, ornithine and gliclazide lead to a significant increase in Y-maze score in comparison to 4 month diabetic rats (4, 4.7, 4.2, 5 and 4.2 vs 1.5 respectively). Data are expressed as mean ± SEM, n = 6. * significantly different from control group, # significantly different from diabetic group at P<0.05 using one way analysis of variance (ANOVA) followed by Tukeys Post Hoc test. Figure 4 shows that 4 months of diabetes caused a significant increase in the transfer latency in the elevated plus maze in comparison to control rats (45 vs 3.6 seconds), while treatment with ferulic acid, cinnamaldehyde, norvalline, citrulline, ornithine and gliclazide lead to a significant decrease in the transfer latency in comparison to 4 month diabetic rats (8, 13, 15, 21, 12, 21 vs 45 seconds respectively). Data are expressed as mean ± SEM, n = 6. * significantly different from control group, # significantly different from diabetic group at P<0.05 using one way analysis of variance (ANOVA) followed by Tukeys Post Hoc test Advanced glycation end products (AGEs) Figure 5 shows that, two and four months diabetic rats had significant increase in serum AGE level in comparison to control rats (276 and 584 vs 161 U/ml respectively). Treatment with ferulic acid, cinnamaldehyde, norvalline, citrulline, ornithine and gliclazide caused a significant decrease in serum AGE level in comparison to 4 month diabetic rats (332, 194, 236, 180, 206 and 219 respectively vs 584 u/ml). * significantly different from control group, # significantly different from diabetic group at P<0.05 using one way analysis of variance (ANOVA) followed by Tukeys Post Hoc test
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DISCUSSION
Diabetes mellitus (DM) is the most common endocrine disorder and currently affects more than 347 million people worldwide (Huang et al., 2012) .It has been well accepted that diabetes results in microvascular and macrovascular complications such as retinopathy, peripheral neuropathy, stroke and coronary heart disease and can also cause complications within the central nervous system (CNS) (Wrighten et al., 2009 ).
In the current study, diabetes induced in rats by STZ injection caused a significant decrease in body weight after 16 weeks. These findings keep pace with previous studies in diabetic rats (Guglielmotto et al., 2012; Michea et al., 2001) . Treatment with aldose reductase inhibitors (ferulic acid, cinnamaldehyde) or arginase inhibitors (citrulline, norvaline, ornithine) for 8 weeks had no effect on body weight.
In the present study, rats subjected to intraperitoneal STZ injection showed increase in blood glucose after 8 and 16 weeks. Similar results were previously reported following STZ injection (Di Filippo et al., 2005 ; Elsner et al., 2000; Reagan et al., 2000) . Treatment with aldose reductase inhibitors (ferulic acid, cinnamaldehyde) or arginase inhibitors (citrulline, norvaline, ornithine) had no action on blood glucose level which indicates that these compounds lack any hypoglycemic action.
Diabetes mellitus is a systemic disease that can cause complications involving both small and large vessels, cranial and peripheral nerves, skin, and eyes. These lesions may lead to hypertension, renal failure, vision loss, neuropathy, myocardial infarction and stroke (J et al., 2009 ).
The present work demonstrated that diabetes was associated with elevation in blood pressure. Similar results were previously reported , 2004) . A previous study has demonstrated enhanced NO generation by arginase inhibition (Santhanam et al., 2008) . Arginase inhibition restores L-arginine for eNOS and limits NO inactivation by superoxide anion which could explain the protective effect of arginase inhibitors against impairment in endothelium-function and reactive oxygen species (ROS) and AGEs levels were significantly decreased following arginase inhibition (Wautier et al., 2001) .
The reduction in blood pressure without alteration in blood glucose level implies that these drugs might be useful in the prevention of diabetes vascular complications without alteration in blood glucose level.
Oxidative stress, causes quenching of nitric oxide by free radicals and prevents its vasodilator effect thus promoting endothelial dysfunction (Salman and Inamdar, 2012 Vijayalakshmi et al., 2012) . In addition, treatment with norvalline, ornithine and citrulline lead to a significant decrease in transfer latency in the elevated plus maze. Similar results were previously reported (Kurata et al., 2011; Li et al., 2014; Lopez-Jaramillo and Teran, 1999). A similar improvement in memory and cognition was observed in rats treated with gliclazide as evidenced by the decrease in transfer latency in the elevated plus maze. Similar results were previously reported following induction of diabetes (Strachan, 2005) .
Chronic hyperglycemia and hyperinsulinemia stimulate the [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] formation of AGEs, which leads to an overproduction of ROS which are the two main mechanisms involved in biological aging and probably the etiopathogeny of Alzheimer's disease (J et al., 2009 ).
In the current study, diabetic rats showed an elevation in serum AGEs level. Similar results were previously reported following induction of diabetes (Cardoso et al., 2012; Guglielmotto et al., 2012) . Several studies have demonstrated the involvement of AGE in micro-and macrovascular complications of diabetes (Radoi et al., 2012) .
Treatment with ferulic lead to a significant decrease in serum AGEs. These findings keep pace with previous studies (Castillo and Silván, 2011; Sompong et al., 2013) . Ferulic acid was shown to reduce the formation of AGEs by acting as an antioxidant, binding amino groups, and inhibiting sugar autoxidation and early Maillard Reaction Products (MRP) degradation (Odjakova et al., 2012) . Treatment with cinnamaldehyde lead to a decrease in AGEs level as previously described (Kumar et al., 2012) . Cinnamaldehyde was shown to inhibit the formation of AGEs through its antioxidant and anti-inflammatory actions (Ho and Chang, 2012) . Treatment with norvalline, citrulline and ornithine lead to decrease AGEs level as shown previously (El-Bassossy et al., 2012a). This might be attributed to the decrease in ROS production. Decrease in AGEs level independent of glucose level has been reported in previous studies (Wautier et al., 2001 
